Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 17% price increase over the past week, likely influenced by its recent announcements and market trends. The company's R&D progress showcase on February 25 ...
This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.
ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...
Alnylam's RNAi TTR Silencing Drug Amvuttra FDA Approved for Transthyretin Amyloidosis Cardiomyopathy
The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.
Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...
The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary transthyretin-mediated amyloidosis.
Stock futures and Treasury yields dipped Friday morning as investors weighed rising uncertainty over trade tariffs. Here are some of Friday's biggest stock movers: Biggest stock gainers Alnylam ...
The approval expands the indication for Amvuttra, which now becomes the first and only therapeutic approved by the FDA for ...
Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback